Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update
$12.5 million in gross financings raised during the quarter, with an additional $9 million raised by Citius Oncology in July 2025, to facilitate LYMPHIR pre-launch initiatives and drive successful ...
What are the potential upside scenarios for LYMPHIR’s commercial launch, and how could they translate into stock price performance?
How does the valuation of the new financing (price per share, discount to market) compare to recent equity offerings by competitors?
What are the projected timelines for LYMPHIR’s FDA approval or regulatory milestones, and how does the recent financing support those timelines?
27 days ago